Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.
Christelle BouchartJean-Luc EngelholmJean ClossetJulie NavezPatrizia LoiYeter GökburunThierry De GrezLaura MansAlain HendliszMaria Antonietta BaliPierre EisendrathDirk Van GestelMatthieu HeinLuigi MorettiJean-Luc Van LaethemPublished in: Therapeutic advances in medical oncology (2021)
iHD-SBRT displays an excellent toxicity profile, also for potentially high-risk patients with radiological direct GI invasion at diagnosis and can be easily integrated in a total neoadjuvant strategy. The oncological outcomes are promising and emphasise the need for further exploration of iHD-SBRT in phase II/III trials.
Keyphrases
- rectal cancer
- locally advanced
- phase ii
- radiation therapy
- high dose
- clinical trial
- open label
- lymph node
- squamous cell carcinoma
- early stage
- radiation induced
- oxidative stress
- prostate cancer
- placebo controlled
- type diabetes
- randomized controlled trial
- cell migration
- double blind
- combination therapy
- pain management
- radical prostatectomy
- metabolic syndrome
- chronic pain
- skeletal muscle
- study protocol
- insulin resistance
- glycemic control
- replacement therapy